This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	
C12N 15/01, 9/04, 1/20, 15/74	

(11) International Publication Number:

WO 99/54453

A1 (43) International Publication Date:

28 October 1999 (28.10.99)

(21) International Application Number:

PCT/DK99/00218

(22) International Filing Date:

20 April 1999 (20.04.99)

(30) Priority Data:

21 April 1998 (21.04.98) DK 0552/98 21 April 1998 (21.04.98) US 60/082,566 21 December 1998 (21.12.98) DK 199801697

(71) Applicant (for all designated States except US): CHR. HANSEN A/S [DK/DK]; Bøge Allé 10-12, DK-2970 Hørsholm (DK).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): HENRIKSEN, Claus, Maxel [DK/DK]; Classensgade 19B, 3. TV., DK-2100 Copenhagen Ø (DK), NILSSON, Dan [DK/DK]; Gefionsbakken 4A, DK-3060 Espergaerde (DK), WALFRIDSSON, Mats [SE/SE]; Valdemars Vag 93, S-224 74 Lund (SE).
- (74) Agent: PLOUGMANN, VINGTOFT & PARTNERS A/S; Sankt Annae Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU. AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(54) Title: NOVEL GENETICALLY MODIFIED LACTIC ACID BACTERIA HAVING MODIFIED DIACETYL REDUCTASE **ACTIVITIES**

(57) Abstract

Genetically modified lactic acid bacteria having a reduced or lacking or enhanced diacetyl reductase activity, and/or activity reductase acetoin butanediol dehydrogenase activity are Such bacteria are used in provided. starter cultures in the production of food products including dairy products where it is desired to have a high content of diacetyl and for reducing or completely removing diacetyl in beverages including beers, fruit juices and certain types of wine, where the presence of diacetyl is undesired.



+ O+DB1341+DB1334 (A) + O+DB1341+MM084 (B)

FOR THE PURPOSES OF INFORMATION ONLY

47

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL Albania ES Spain LS Lesotho SI Slovania AM Armenia FI Finland LT Lithuania SK Slovakia AM Armenia FI Finland LT Lithuania SK Slovakia AT Austria FR France LU Luxembourg SN Senegal AU Australia GA Gabon LV Latvia SZ Swaziland AZ Azerbaijan GB United Kingdom MC Monaco TD Chad AZ Azerbaijan GE Georgia MD Republic of Moldova TG Togo BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BA Bosnia and Herzegovina GE Georgia MG Madagascar TJ Tajikistan BB Barbados GR Gineca MK The former Yugoslav TM Turkmenistan BB Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BB Belgium HU Hungary MI Mali TT Trinidad and Tobago BG Bulgaria HU Hungary MI Mali UA Ukraine BJ Benin IE Ireland MR Mongolia UA Ukraine BR Brazil II. Israel MR Mauritania UG Uganda BR Brazil II. Israel MR Mauritania UG Uganda BR Brazil II. Israel MR Mauritania UG Uganda CA Canada IT Italy MX Mexico UZ Uzbekistan CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CF Central African Republic KE Kenya NI. Netherlands YU Yugoslavia CG Congo KE Kenya NI. Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway CH Switzerland KR Republic of Korea PI Portugal CM Cameroon Republic of Korea PI Portugal CM Romania RU Russian Federation SM Smarter SM Smarter Russian Federation SM Smarter PI Portugal CM Republic of Monacdonia P		Couch about to 1211	•	•				
	AM AT AU AZ BB BB BB BF BG BJ BR BY CA CF CG CH CI CM CN CU DE DK	Albania Armenia Austria Australia Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon China Cuba Czech Republic Germany Denmark	FI FR GA GB GC GN GR HU IS IT JP KE KG KP KR KZ LC LL LK	Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea Kazakstan Saint Lucia Liechtenstein Sri Lanka	LT LU LV MC MD MG MK MI MN MN MR MV MX NE NI NO NZ PI RO RU SD SE	Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mali Mongolia Mauritania Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal Romania Russian Federation Sudan Sweden	SK SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU	Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe

WO 99/54453 PCT/DK99/00218

NOVEL GENETICALLY MODIFIED LACTIC ACID BACTERIA HAVING MODIFIED DIACETYL REDUCTASE ACTIVITIES

5 FIELD OF THE INVENTION

The present invention relates to the field of manufacturing food products by means of lactic acid bacterial cultures. Specifically the invention provides novel genetically modified strains of lactic acid bacteria that are modified to have enhanced or reduced diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity. Such modified bacteria are particularly useful in the manufacturing of food products having either a reduced or an increased content of the flavour compound diacetyl.

15

TECHNICAL BACKGROUND AND PRIOR ART

Lactic acid bacteria are used extensively as starter cultures in the food industry in the manufacturing of fermented products including milk products such as e.g. yoghurt and cheese, meat products, bakery products, wine and vegetable products. Lactococcus species including Lactococcus lactis are among the most commonly used lactic acid bacteria in dairy starter cultures. Several other lactic acid bacteria such as Leuconostoc species, Pediococcus species, Lactobacillus species, Oenococcus species and Streptococcus species are also commonly used in food starter cultures.

25

When a lactic acid bacterial starter culture is added to milk or any other food product starting material under appropriate conditions, the bacteria grow rapidly with concomitant conversion of citrate, lactose or other sugar compounds into lactic acid/lactate and possibly other acids including acetate, resulting in a pH decrease. In addition, several other metabolites are produced during the growth of lactic acid bacteria. These metabolites include ethanol, formate, acetaldehyde, α-acetolactate, acetoin, diacetyl, carbon dioxide and 2,3 butylene glycol (butanediol).

20

Among these metabolites, diacetyl (2,3-butanedione) is an essential flavour compound in dairy products such as butter, yoghurt, starter distillate, margarine, buttermilk and cheese. However, its presence in other products, such as fruit juices, beers and wines, is undesirable, as it imparts a buttery or toffee taste and is the agent responsible for the so-called sarcina sickness of beer. The compound is formed during fermentation of lactic acid bacterial species of e.g. *Lactococcus*, *Leuconostoc* and *Lactobacillus* by an oxidative decarboxylation of α-acetolactate which is formed from two molecules of pyruvate by the action of α-acetolactate synthase (ALS).

- 10 Diacetyl reducing enzymes, commonly termed diacetyl reductases (DR) (acetoin:NAD oxidoreductases E.C. 1.1.1.5), have been observed from many different sources, notably animal tissues (Provecho et al., 1984), bacteria including *Lactococcus* (formerly *Streptococcus*) *lactis* (Crow, 1990; Arora et al., 1978), *Bacillus* species and *Enterobacter* species (Giovannini et al. 1996), and yeast (Gibson et al., 1991).
- Boumerdassi et al. 1997 disclosed a mutated *Lactococcus lactis* strain having DR activity that was increased by three times relative to the activity of the parent strain. In Arora et al. 1978 and Kulia & Ranganathan 1978 are disclosed mutants of *Lactococcus lactis* having a reduced diacetyl activity when grown in non fat dry milk and citrate medium, respectively.

Generally, the term "diacetyl reductase" ("DR") encompasses several enzymatic activities such as diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity which carry out the following enzymatic reactions; diacetyl + NAD(P)H ---> acetoin + NAD(P)+, acetoin + NAD(P)H <---> butanediol + NAD(P)+, respectively. Thus, *L. lactis* has been reported to possess two diacetyl reductases with activity for both diacetyl and acetoin. Both of these enzymes use NADH as cofactor (Crow, 1990).

Leuconostoc species including Leu. pseudomesenteroides are typically used in mixed starter cultures together with Lactococcus lactis subsp. lactis and Lactococcus lactis subsp. lactis biovar. diacetylactis in the production of dairy products. A significant role of Leuconostoc species in such mixed cultures is to remove the acetaldehyde produced by the accompanying strains e.g. in the production of buttermilk and fresh cheeses. However, Leuconostoc strains will also remove diacetyl by reducing it into

acetoin and/or butanediol, a characteristic that is generally undesirable in the production of dairy products. The enzyme responsible for the reduction of diacetyl, diacetyl reductase, is highly expressed in *Leuconostoc* species such as *Leu. pseudomesente-roides* which species is known to have about 100 times higher diacetyl reductase activity than *L. lactis*.

Thus, one primary objective of the present invention is to provide lactic acid bacterial cultures of species, including *Leuconostoc* species, that inherently have one or more DR activities which, relative to the naturally occurring strains, has reduced or substantially eliminated DR activities under specific cofactor conditions. By providing such strains to the industry, it has become possible to produce lactic acid bacterial fermented food products having a desirably high content of diacetyl.

Another objective of the invention is to provide lactic acid bacterial strain that, relative to the presently available strains, has a strongly enhanced DR activities. Using such strains which utilise diacetyl as a substrate it is possible to reduce or remove diacetyl in food products where the presence of this flavour compound is undesirable.

20 SUMMARY OF THE INVENTION

Accordingly, the invention provides in a first aspect a genetically modified lactic acid bacterium, including the *Leuconostoc pseudomesenteroides* strains DSM 12099 and DSM 12465 and lactic acid bacteria essentially having the diacetyl reductase characteristics of these strains, that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, said modified bacterium,

- 30 (i) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADH and not containing NADPH, or
 - (ii) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADPH and not containing NADH, or

10

- (iii) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing both NADH and NADPH, or
- 5 (iv) is substantially incapable of butanediol dehydrogenase activity in a medium containing NAD+ and not containing NADP+, or
 - (v) is substantially incapable of butanediol dehydrogenase activity in a medium containing $NADP^{+}$ and not containing NAD^{+} , or
 - (vi) is substantially incapable of butanediol dehydrogenase activity in a medium containing both NAD^+ and $NADP^+$,
- where the bacterium prior to being modified is capable of having at least one of said enzymatic activities under said cofactor conditions.
- In a further aspect, the invention relates to a genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, including the *Leuconostoc pseudomesenteroides* strains DSM 12099 and DSM 12465 and lactic acid bacteria essentially having the diacetyl reductase characteristics of these strains, subject to the limitation, that the lactic acid bacterium is not *Lactococcus lactis*.
- In a still further aspect, the invention relates to a genetically modified lactic acid bacterium that has no detectable diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity, subject to the limitation, that the lactic acid bacterium is not *Lactococcus lactis*.
- 30 In other further aspects, the invention relates to a genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have an enhancement of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity which is at least 10

times, including the *Lactococcus lactis* subsp. *lactis* strain DSM 12096 and lactic acid bacteria essentially having the diacetyl reductase characteristics of that strain.

In a still further aspect, the invention pertains to a starter culture composition comprising such a genetically modified bacterium.

There is also provided a method of preparing a fermented food product, comprising adding an effective amount of a bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, or a composition comprising such a bacterium to a food product starting material wherein the bacterium or the composition is incapable of having at least one enzymatic activity selected from the group consisting of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity and keeping the starting material under conditions where the bacterium or the starter culture composition is capable of fermenting said starting material to obtain the fermented food, and a fermented food product obtainable by such a method which product has a content of diacetyl which is at least 10% higher than that of a product fermented under identical conditions with a parent strain for the genetically modified bacterium.

20

In yet another aspect, the invention relates to a method of producing a food product, comprising adding an effective amount of a bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have an enhancement of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, or a composition comprising such a bacterium to a food product starting material that contains at least one of diacetyl, acetoin and butanediol, and keeping the starting material under conditions where the genetically modified lactic acid bacterium has at least one enzymatic activity selected from the group consisting of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity to obtain a product having a reduced content of diacetyl.

DETAILED DISCLOSURE OF THE INVENTION

It is, as it is mentioned above, an important objective of the present invention to provide lactic acid bacteria that has a reduced capability to convert diacetyl in a fermented food product to acetoin and/or butanediol. Accordingly, in one aspect the genetically modified lactic acid bacterium is a bacterium that, relative to the lactic acid bacterium from which it is derived, is modified so as to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, said bacterium, when grown under at least one of the above cofactor conditions, where the bacterium prior to being mutated is capable of having at least one of said enzymatic activities, is substantially incapable of at least one of said activities. As used herein, the term "substantially incapable" indicates that the respective enzymatic activities can not be detected by the assay procedures described herein.

15

As used herein, the expression "lactic acid bacterium" refers to a group of grampositive, microaerophilic or anaerobic bacteria having in common the ability to ferment sugars and citrate with the production of acids including lactic acid as the predominantly produced acid, acetic acid, formic acid and propionic acid. The industrially most useful lactic acid bacteria are found among Lactococcus species, Streptococcus species, Lactobacillus species, Leuconostoc species, Oenococcus species and Pediococcus species. In the dairy industry, the strict anaerobes belonging to the genus Bifidobacterium is generally included in the group of lactic acid bacteria as these organisms also produce lactic acid and are used as starter cultures in the production of dairy products.

It will be appreciated that the term "genetically modified" as used herein indicates any modification of DNA sequences coding for genes involved in the expression of DR activities including modifications of sequences that regulate the expression of genes coding for such enzymatic activities. Accordingly, genetic modification can be based on construction or selection of mutants of lactic acid bacteria or it can be based on recombinant DNA-technology. When the term "diacetyl reductase" or "DR" is used herein it refers to any of the three mentioned specific activities, i.e. diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity.

15

As used herein the term "mutant" is used in the conventional meaning of that term i.e. it refers to strains obtained by subjecting a lactic acid bacterial strain to any conventionally used mutagenization treatment including treatment with a chemical mutagen such as ethanemethane sulphonate (EMS) or N-methyl-N'-nitro-N-nitroguanidine (NTG), UV light or to spontaneously occurring mutants which are selected on the basis of a modified DR activity. Although it is presently preferred to provide the genetically modified bacteria according to the invention by random mutagenesis or by selection of spontaneously occurring mutants, i.e. without the use of recombinant DNA-technology, it is envisaged that mutants of lactic acid bacteria can be provided by such technology including site-directed mutagenesis and PCR techniques and other *in*

vitro or in vivo modifications of DNA sequences coding for DR activities or sequences

regulating the expression of genes coding for the DR activities, once such sequences have been identified and isolated.

It is also possible to construct genetically modified bacteria according to the invention by conventional recombinant DNA-technology including insertion of sequences coding for DR activities, e.g. by replacing a native promoter for such coding sequences by a foreign promoter which either enhances or reduces the expression of the coding sequences. It is also possible to derive lactic acid bacterial strains according to the invention from species that do not have an inherent capability to produce DR activities by inserting genes coding for such activities isolated from a different organism comprising such genes. The source of such genes may be bacterial species, yeast species or mammal species. Additionally, it is envisaged that genetically modified bacteria according to the invention can be constructed by modifying metabolic pathways in a lactic acid bacterium that are not directly involved in DR pathways. It will be appreciated that the expression "under cofactor conditions" as used herein indicates the absence/presence in an appropriate medium of any non-protein substance required for biological activity of any of the enzyme activities according to the invention, such as NAD+, NADH, NADP+ and NADPH.

A genetically modified bacterium having a reduced diacetyl activity can be selected from any kind of lactic acid bacterial species which has an inherent DR activity, including *Lactococcus* spp., *Streptococcus* spp., *Lactobacillus* spp., *Leuconostoc* spp

30

such as Leuconostoc pseudomesenteroides, Pediococcus spp., Oenococcus spp. and Bifidobacterium spp.

As mentioned above, the invention relates in another aspect to a genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, including the *Leuconostoc pseudomesenteroides* strains DSM 12099 and DSM 12465 and lactic acid bacteria essentially having the diacetyl reductase characteristics of these strains, subject to the limitation that the modified bacterium is not *Lactococcus lactis*.

However, in particularly useful embodiments, the above genetically modified bacterium is one that under cofactor conditions, where the bacterium prior to being genetically modified is capable of having at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, is substantially incapable of at least one of said enzymatic activities.

Such a bacterium includes a bacterium that is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADPH and not containing NADPH, a bacterium that is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADPH and not containing NADH, a bacterium that is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing both NADH and NADPH, a bacterium that is substantially incapable of butanediol dehydrogenase activity in a medium containing NAD and not containing NADP, a bacterium that is substantially incapable of butanediol dehydrogenase activity in a medium containing NADP and not containing NAD and a bacterium that is substantially incapable of butanediol dehydrogenase activity in a medium containing NADP and not containing NAD and a bacterium that is substantially incapable of butanediol dehydrogenase activity in a medium containing both NAD and NADP.

In a further aspect, the invention provides a genetically modified lactic acid bacterium that has no detectable diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity. Such a bacterium is selected from any of the

above-mentioned lactic acid bacterial species, subject to the limitation, that the bacterium is not *Lactococcus lactis*.

A genetically modified bacterium having reduced or no detectable DR activities can be derived from any lactic acid bacterial species which has an inherent DR activity, including Lactococcus spp. such as Lactococcus lactis subsp. lactis biovar. diacetylactis and Lactococcus lactis subsp. lactis, Streptococcus spp. including Streptococcus thermophilus, Lactobacillus spp., Leuconostoc spp. including Leuconostoc pseudomesenteroides., Pediococcus spp.. Oenococcus spp. and Bifi-dobacterium spp.

Although it may be preferred that the modified bacterium has substantially no detectable DR activities, a bacterium that is modified to have a reduction of one or more of the above activities is also encompassed by the invention. Thus, a useful bacterium according to the invention is one that has a reduction in any of the DR activities which, relative to the bacterium from which it is derived, is at least 25% such as at least 50% including at least 75% e.g. at least 90%. Thus, the genetically modified bacterium according to the invention preferably has a DR activity reduction which is reduced by at least 25 times for anyone of the enzymatic activities such as at least 50 times, including at least 100 times or even at least 500 times, relative to the strain from which it is derived.

When a modified lactic acid bacterial strain according to the invention is added to a food product starting material, such as e.g. milk, wherein the bacterium is incapable of having at least one of the above DR enzymatic activities and the starting material is kept under conditions where the strain is capable of fermenting said starting material to obtain a fermented food product, the resulting food product preferably has an increased content of diacetyl which is at least 1.1 times higher, such as at least 2 times higher, including at least 5 times higher or even at least 10 times higher, relative to a similar food product which is fermented using the strain from which the modified strain is derived.

Thus in one embodiment, the modified bacterium according to the invention is derived by subjecting a parent lactic acid bacterial strain that under appropriate cofactor

conditions is capable of having diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity to a mutagenization treatment and selecting a strain that is substantially incapable of at least one of said enzymatic activities under identical cofactor conditions.

5

The present invention relates in a further aspect to a genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have an enhancement of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity which is at least 10 times, including the *Lactococcus lactis* subsp. *lactis* strain DSM 12096 and lactic acid bacteria essentially having the diacetyl reductase characteristics of that strain.

It was found that it is possible to provide genetically modified lactic acid bacteria that have a significant enhancement of the specific DR activities. Thus, by fermenting a material or a medium having a content of diacetyl with such a genetically modified bacterium it is possible to obtain a final product wherein essentially all of the diacetyl has been converted to butanediol which is without the buttery flavour of diacetyl. Thus, the genetically modified bacterium according to the invention preferably has an activity enhancement which is at least 10 times for anyone of the enzymatic activities such as at least 50 times or even at least 100 times, relative to the strain from which it is derived.

A genetically modified bacterium having enhanced DR activities can be derived from any lactic acid bacterial species which has an inherent DR activity, including

25 Lactococcus spp. such as Lactococcus lactis subsp. lactis biovar. diacetylactis and Lactococcus lactis subsp. lactis, Streptococcus spp. including Streptococcus thermophilus, Lactobacillus spp., Leuconostoc spp. including Leuconostoc pseudomesenteroides., Pediococcus spp. and Bifidobacterium spp.

30 It will be appreciated that such modified bacteria can be a spontaneous mutant or be provided by subjecting a lactic acid bacterium that has inherent DR activities to a mutagenization treatment as described above or by inactivating or deleting one or more genes involved in the expression of the DR activities using conventional recombinant DNA-technology.

The genetically modified bacteria according to the invention are useful as starter cultures in the production of food products. Accordingly, in a further important aspect, the invention relates to a starter culture composition comprising a bacterium according to the invention either having enhanced or a reduced or eliminated DR activities.

Typically, such a composition comprises the bacteria in a concentrated form including frozen, dried or freeze-dried concentrates typically having a concentration of viable cells which is in the range of 10⁴ to 10¹² cfu per g including at least 10⁴ cfu per gram of the composition, such as at least 10⁵ cfu/g, e.g. at least 10⁶ cfu/g, such as at least 10⁷ cfu/g, e.g. at least 10⁸ cfu/g, such as at least 10⁹ cfu/g, e.g. at least 10¹⁰ cfu/g, such as at least 10¹⁰ cfu/g, such as at least 10¹¹ cfu/g of the composition. The composition may as further components contain cryoprotectants and/or conventional additives including nutrients such as yeast extract, sugars and vitamins.

15

As it is normal in the production of lactic acid bacterial fermentation processes to apply mixed cultures lactic acid bacteria, the composition will in certain embodiments comprise a multiplicity of strains either belonging to the same species or belonging to different species. A typical example of such a useful combination of lactic acid bacteria in a starter culture composition is a mixture of a Leuconostoc spp. and one or more Lactococcus spp. such as Lactococcus lactis subsp. lactis or Lactococcus lactis subsp. lactis biovar. diacetylactis. Such a mixed culture can be used in the manufacturing of fermented milk products such as buttermilk and cheese. It will be understood that in such a mixed culture of lactic acid bacteria, one or more of the strain components may be a modified bacterium according to the invention.

It is also an objective of the invention to provide a method of preparing a fermented food product based on the use of the genetically modified bacteria of the invention which have reduced or lacking DR activities. In its broadest aspect, such a method comprises that an effective amount of such bacteria or a composition comprising the bacteria are added to a food product starting material wherein the bacterium or the composition is incapable of having at least one of the above DR enzymatic activities and keeping the starting material under conditions where the bacterium or the starter

culture composition is capable of fermenting said starting material to obtain a fermented food product.

Useful food product starting materials include any material which is conventionally subjected to a lactic acid bacterial fermentation step such as milk, vegetable materials, meat products, fruit juices, must, doughs and batters. The fermented products which are obtained by the method include as typical examples dairy products such as cheese including fresh cheese products, and buttermilk.

10 As it is mentioned above, the use in food starter cultures of bacteria according to the invention that have a reduced or lacking DR activity will result in final products having a content of the desired flavour compound diacetyl which is higher than would otherwise be obtained if a non-modified lactic acid bacterium was used. Accordingly, it is an important aspect of the invention to provide a fermented food product obtainable by the above method which product has a content of diacetyl which is at least 10% higher such as at least 20% higher or at least 30% higher than that of a product fermented under identical conditions with a parent strain for the genetically modified bacterium. Examples of such food products include milk-based products such as cheese and buttermilk, vegetable products, meat products, fruit juices, wines and 20 bakery products.

As shown in the below Examples, when the DR mutant MM084 is used as a component of a mixed flavour-forming starter culture for the fermentation of one of the above starting materials, the mutant has a significant effect on the diacetyl stability during storage of the resulting fermented product.

Thus, an advantageous feature of the fermented food product according to the invention is that the food product can be stored for several weeks with less reduction in the diacetyl content than is the case with a food product fermented under identical conditions with the parent strain of the genetically modified bacterium. Thus, in one particularly useful embodiment, the fermented product is one which at least 10% of its initial diacetyl content is retained after storage for 20 days or more at about 4°C. when stored under appropriate storage conditions, such as at least about 20% of its initial diacetyl content e.g. at least about 30% and preferably at least about 40% e.g.

at least about 50% of its initial diacetyl content is retained after storage for 20 days or more at about 4°C. This improvement implies that a fermented food product manufactured by use of the above mixed starter culture can be stored for an extended period of time without loosing its desired flavour.

5

Whereas in many lactic acid bacterial fermented food products it is desirable to have a high content of diacetyl, this may be undesirable in other products. This is in particular the case in beverages such as fruit juices, beers and other yeast fermented beverages including certain wines, where diacetyl imparts to the products a buttery or toffee taste. In beers a diacetyl content above the threshold level gives rise to the so-called sarcina sickness. It is therefore an interesting aspect of the invention to provide a method of producing a food product having a reduced content of diacetyl.

This method comprises adding an effective amount of a lactic acid bacterium that has been modified to have at least one increased DR activity or a composition containing such a bacterium to a food product starting material that contains at least one of diacetyl, acetoin and butanediol, and keeping the starting material under conditions where the genetically modified lactic acid bacterium has at least one enzymatic activity selected from the group consisting of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity to obtain a product having a reduced content of diacetyl. In useful embodiments the products resulting from such a method have no detectable content of diacetyl.

The invention will now be described in further details in the following non-limiting examples and the drawings wherein

Fig. 1. shows native-PAGE gels containing cell free extracts of wild-type strain of *Leu.* pseudomesenteroides DB1334. The gels were incubated with diacetyl + NADH (A); butanediol + NAD+ (B); and acetoin + NADH (C), and stained with Meldola's blue and MTT. 2, 4, and 8 μg of protein, respectively were loaded onto each gel;

Fig. 2 shows native-PAGE gels containing cell free extracts of wild-type strain of *Leu.* pseudomesenteroides DB1334 and mutant strain MM084 stained with the zymogram technique. The gels were incubated with diacetyl + NADPH (A) or butanediol +

NADP $^+$ (B). MM084 was loaded in lanes 1-4 and DB1334 in lanes 5, 7 and 9. Approximately 6 μg of protein was loaded in each lane;

Fig. 3 illustrates the diacetyl content in reconstituted skimmed milk fermented by the mixed cultures A and B during fermentation and storage. The reconstituted skimmed milk was fermented at 22°C in non-shaken bottles and subsequently stored at 4°C, and

Fig. 4 illustrates the diacetyl content in sour cream fermented with the mixed cultures 10 C and D during fermentation and storage. The cream was fermented at 22°C and subsequently stored at 4°C.

EXAMPLE 1

15

Construction of a NADH-dependent diacetyl reductase mutant of *Leuconostoc* pseudomesenteroides

1.1. Summary of experiments

20

Partially purified NADH-dependent diacetyl reductase from Leuconostoc pseudomesenteroides showed that the enzyme is responsible for at least three enzymatic reactions: (i) diacetyl + NADH ---> acetoin + NAD+; (ii) acetoin + NADH ----> butanediol + NAD+; and (iii) butanediol + NAD+ ---> acetoin + NADH. The enzymatic properties of diacetyl reductase were demonstrated by staining native PAGE gels using the zymogram technique as described in the following. Using this technique, the immobilised enzyme is allowed to react with a substrate and cofactor with a subsequent dye staining. The same technique was also used to screen an ethanemethane sulphonate (EMS) mutagenized Leu. pseudomesenteroides population for the absence of diacetyl reductase (butanediol dehydrogenase activity) activity by direct staining of colonies immobilised onto nitrocellulose membranes. Enzyme activity measurements from cell extracts showed that the mutant possessed only minute diacetyl reductase activity, no acetoin reductase or butanediol dehydrogenase activity when reacting with NADH or NAD+. However, activities comparable to the wild-type

strain were obtained when using NADPH or NADP⁺ as cofactors, indicating the presence of two distinct diacetyl reductases in *Leu. pseudomesenteroides*.

In this example, the isolation and characterisation of a mutant strain of *Leu*.

5 pseudomesenteroides that is defective with respect to an NADH-dependent diacetyl reductase is described.

1.2. Materials and Methods

10 (i) Bacterial strain

A wild-type strain of *Leu. pseudomesenteroides* DB1334 (Chr. Hansen Culture Collection (CHCC) 2114) was used in the experiment.

15 (ii) Cultivation conditions

Leu. pseudomesenteroides was cultivated in M17 medium (Terzaghi & Sandine, 1975) supplemented with 0.5% glucose at 25°C under anaerobic conditions.

20 (iii) Mutagenesis

Leu. pseudomesenteroides was cultivated in 10 ml M17 (0.5% glucose) for 3 days followed by cultivation for 120 minutes in the presence of 150 μl of EMS. After EMS treatment, 0.2 ml of the culture was inoculated into ten tubes each containing 10 ml of M17 and incubated for 3 days for phenotypic expression. The mutation frequency was monitored by plating 0.1 ml from each tube onto M17 plates containing 500 μg/ml of streptomycin.

(iv) Colony screening for mutants

30

Cells having been subjected to mutagenization were plated on M17 (0.5% glucose) and incubated anaerobically for 2 days at 25°C and subsequently streaked onto duplicate M17 plates. After another 2 days of incubation one of the duplicate plates was used for screening. The colonies were transferred onto a nitrocellulose membrane

and soaked for 1.5 minutes in chloroform for cell lysis. After cell lysis, the membrane was washed with distilled water and dried for 20 minutes. The membrane was next incubated for 30 minutes in a solution containing 0.5 M Na-phosphate buffer (pH 6.1), 72 mM butanediol, 1 mM NAD⁺, 0.02 mM Meldola's blue (8-Dimethylamino-2,3-benzophenoxazine) 0.8 mM MTT (3-[4,5-Dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide; Thiazolyl blue).

(v) Protein electrophoresis

10 Using 4-20% Tris-HCl gradient gels with Tris-Glycine (pH 8.3) as running buffer, native-PAGE was run at 150 V for 2.5 hours. Staining of native gels was performed both with 0.25% Coomassie brilliant blue in 10% acetic acid and 40% methanol and with the zymogram technique (see below). SDS-PAGE was run using a 12% separation gel, 4% stacking gel and with Tris-Glycine (pH 8.3) as running buffer at 200 V for 45 minutes.

(vi) Zymogram staining of gels

Zymogram staining of native-PAGE gels for identification of diacetyl reductase activity and butanediol dehydrogenase activity was performed as follows: for diacetyl reductase activity the gel was incubated for 15 minutes with 12 mM diacetyl, 1.5 mM NADH, 0.5 M Na-phosphate buffer (pH 6.1) and for butanediol dehydrogenase activity the gel was incubated for 15 minutes with 72 mM butanediol, 1 mM NAD⁺, 0.5 M Na-phosphate buffer. The gel was subsequently incubated for 30 minutes under dry conditions before the addition of a solution consisting of 0.02 mM Meldola's blue (8-Dimethylamino-2,3-benzophenoxazine) 0.8 mM MTT (3-[4,5-Dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide; Thiazolyl blue) in 100 mM phosphate buffer (pH 8.2) (Provecho et al, 1984; Gibson et al, 1991). Visible bands appeared within 20 minutes.

30 (vii) Preparation of cell free extracts

Leu. pseudomesenteroides was cultivated in M17 (0.5% glucose). The cells were harvested in the exponential growth phase by centrifugation at 6000 rpm for 15 minutes and washed in cold 50 mM Na-phosphate buffer (pH 6). The pellet was

resuspended in cold 50 mM Na-phosphate buffer (pH 6) and sonicated for 3 x 2 minutes. The sonicated cell mixture was centrifuged at 6000 rpm for 15 min, and the supernatant was stored at -20° C until analysed for protein content and enzymic activities.

5

(viii) Enzyme activity measurements

Diacetyl reductase activity was measured spectrophotometrically by monitoring the oxidation of NADH at 340 nm in a reaction mixture with the following composition:

10 50 mM Na-phosphate buffer (pH 6.1), 36 mM diacetyl and 0.5 mM NADH. Butanediol dehydrogenase activity was measured by monitoring the reduction of NAD⁺ at 340 nm in a reaction mixture with the following composition: 50 mM phosphate buffer (pH 6.1), 72 mM butanediol and 1 mM NAD⁺. Acetoin reductase activity was measured by monitoring the oxidation of NADH at 340 nm in a reaction mixture with the

15 following composition: 50 mM Na-phosphate buffer (pH 6.1), 36 mM acetoin and 0.5 mM NADH.

Lactate dehydrogenase was measured by monitoring the oxidation of NADH at 340 nm in a reaction mixture with the following composition: 50 mM Tris-acetate buffer 20 (pH 6), 0.5 mM fructose-1,6-diphosphate, 25 mM pyruvate and 0.5 mM NADH.

The specific enzymatic activities were expressed as micromoles of converted substrate per milligram of protein per minute (equivalent to units per milligram protein).

25 (ix) Protein determination

Protein content was measured by using the BCA Protein Assay Reagent (Pierce) with bovine serum albumin as the standard.

30 (x) Milk fermentation

Boiled (UB) 9.5% reconstituted skim-milk (RSM) supplemented with 100 ppm of acetaldehyde and 100 ppm of diacetyl was used as fermentation substrate. The milk

was inoculated with DB1334 and MW008 and samples were analysed by headspace. GC every hour for twenty hours (Richelieu et al., 1997).

1.3. Results

5

(i) Native PAGE staining

Partially purified diacetyl reductase from Leu. pseudomesenteroides was separated on native gradient PAGE gels and stained with both Coomassie brilliant blue and with the 10 zymogram technique. With the zymogram technique, the gels were incubated with diacetyl + NADH, acetoin + NADH or with butanediol + NAD+. The gels were subsequently stained with Meldola's blue and MTT. With the three different incubation mixtures a protein band with the same molecular weight was visualised. In the presence of diacetyl + NADH, or with acetoin + NADH, the gel becomes saturated 15 with NADH. However, at the position where diacetyl reductase is immobilised, the enzyme converts diacetyl + NADH into acetoin + NAD+ or acetoin + NADH into butanediol + NAD+. In the following incubation with Meldola's blue and MTT, these reagents react with the reduced cofactor (NADH) and the gel becomes purple except where diacetyl reductase is located. The band corresponding to diacetyl reductase 20 becomes colourless. Incubation with butanediol and NAD* results in the reverse result. In this case, butanediol + NAD+ is converted to acetoin + NADH resulting in a purple band with a colourless background. No reaction was observed with acetoin + NAD+. Fig. 1 shows a native-PAGE gel incubated with different substrates and cofactors followed by staining with MTT and Meldola's blue.

25

(ii) Screening of EMS mutagenized DB1334

Based on the result from the zymogram staining, an EMS mutagenized DB1334 population was screened by incubating the cells in a reaction mixture of butanediol + NAD⁺. Lysed cells with an intact diacetyl reductase (butanediol dehydrogenase activity) were stained purple whereas a diacetyl reductase (DR) mutant should become colourless. Approximately 1700 clones were screened and 1 clone appeared colourless. This putative DR mutant was restreaked three times and repeatedly stained

with Meldola's blue and MTT before regarded as true mutant. The selected mutant was designated MW008.

A sample of the mutant *Leu. pseudomesenteroides* MW008 strain was deposited in accordance with the Budapest Treaty with the Deutsche Sammlung vor Mikroorganismen und Zellkulturen (DSMZ), Marschenroder Weg, 1b, D-38124 Braunschweig on 7 April 1998 under the Accession No. DSM 12099.

(iii) Enzyme activity measurements

10

Cell-free extracts of the DR mutant (MW008) and DB1334 were used for measuring the diacetyl reductase, butanediol dehydrogenase, acetoin reductase and lactate dehydrogenase activities. Lactate dehydrogenase activity measurements were used as a positive control for enzymatic activity of the strains. The results of the enzyme activities are summarised in Table 1.1.

Table 1.1. Diacetyl reductase (DR), acetoin reductase (AR), butanediol dehydrogenase (BUTDH) and lactate dehydrogenase (LDH) activities from cell free extracts of DB1334 and MW008.

-	_	
")	r	٦
_	L	J

strain		specific activ	ity in U/mg of pr	otein
	DR1	AR ¹	BUTDH ²	LDH1
DB1334	2.81	0.81	0.34	17.70
MW008	0.017	n.d	n.d	22.10

¹ with NADH, 2 with NAD †

n.d = not detectable, activities below the detection limit < 0.005 U/mg.

25 1.4. Conclusions

Based on the zymogram staining of native PAGE gels containing partially purified diacetyl reductase derived from *Leu. pseudomesenteroides* it was concluded that this enzyme has activity for diacetyl + NADH, acetoin + NADH, and butanediol + NAD⁺.

30 No activity was observed with acetoin and NAD⁺. Screening of a mutagenized population of *Leu. pseudomesenteroides* was performed by incubating the cells with

butanediol and NAD⁺. After staining, cells with an intact DR were stained purple, whereas a mutant became colourless. Cell-free extract from the DR mutant confirmed the result from the screening procedure, since essentially no activity was found with diacetyl + NADH, acetoin + NADH or butanediol + NAD⁺.

5

After isolation of the NADH-dependent DR mutant, this strain was used for fermentation of milk supplemented with diacetyl and acetaldehyde. Surprisingly, the mutant strain was able to reduce diacetyl despite the absence of NADH-dependent diacetyl reductase activity. Measurements of cell free extract of the mutant with diacetyl + NADPH, acetoin + NADPH and butanediol + NADP+ showed similar activities as the wild type. Therefore, it was most likely that DB1334 has two diacetyl reductases responsible for diacetyl degradation. In order to prevent diacetyl reduction during milk fermentation, also the NADPH-dependent diacetyl reductase of DB1334 must be mutated.

15

EXAMPLE 2

Demonstration of both NADH- and NADPH-dependent diacetyl reductase activities in

Leuconostoc pseudomesenteroides and construction of mutant strains totally blocked in diacetyl reductase activities

2.1. Summary of experiments

25 In Example 1 the construction of a diacetyl reductase mutant with no essentially activity for diacetyl + NADH is described. However, the mutant possessed diacetyl reductase activities as the wild-type strain when using NADPH as cofactor. This strain was able to degrade diacetyl at the same rate as the wild-type strain. The NADH-dependent diacetyl reductase mutant was subjected to further mutagenization and screened for mutants incapable of reducing diacetyl both in the presence of NADH and NADPH as cofactors.

2.2. Materials and Methods

(i) Bacterial strains

5 Leuconostoc pseudomesenteroides DB1334 (CHCC2114), MW008 (NADH-dependent diacetyl reductase mutant, see Example 1) and MM084 (NADH-, NADPH-dependent diacetyl reductase mutant, this Example).

(ii) Cultivation conditions

10

DB1334, MW008 and MM084 were cultivated on M17 (0.5% glucose) plates, or in liquid medium, at 25°C under anaerobic conditions.

(iii) Mutagenesis

15

MW008 was cultivated in 10 ml M17 (0.5% glucose) for three days followed by cultivation for 120 minutes in the presence of 150 μl of EMS. After EMS treatment, 0.2 ml of the culture was inoculated into ten tubes each containing 10 ml of M17 and incubated for 3 days for phenotypic expression. The mutation frequency was 20 monitored by plating 0.1 ml from each tube on M17 plates containing 500 μg/ml of streptomycin.

(iv) Colony screening

- 25 Mutated cells were plated on M17 (0.5% glucose) and incubated for 2 days at 25°C anaerobically and streaked onto duplicate M17 plates. After another 2 days of incubation one of the duplicate plates was used for screening. The colonies were transferred onto a nitrocellulose membrane and soaked for 1.5 minutes in chloroform for cell lysis. After cell lysis, the membrane was washed with distilled water and dried
- 30 for 20 minutes. The membrane was subsequently incubated for 30 minutes in a solution containing; 0.5 M Na-phosphate buffer (pH 6.1), 72 mM butanediol, 1 mM NAD⁺ or NADP⁺, 0.02 mM Meldola's blue (8-Dimethylamino-2,3-benzophenoxazine), 0.08 mM MTT (3-[4,5-Dimethylthiazol-2yl] 2,5-diphenyltetrazolium bromide; Thiazolyl blue).

(v) Protein electrophoresis

Native-PAGE was run at 150 V for 2.5 hours using 4-20% Tris-HCl gradient gels with Tris-Glycine (pH 8.3) as running buffer. Staining of native gels was performed with the zymogram technique (see below).

(vi) Zymogram staining of gels

Zymogram staining of native-PAGE gels for identification of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity was performed as follows: for diacetyl reductase activity the gel was incubated for 15 minutes with 12 mM diacetyl, 1.5 mM NADH or NADPH, 0.5 M Na-phosphate buffer (pH 6.1), for acetoin reductase activity the gel was incubated for 15 minutes with 36 mM acetoin, 1.5 mM NADH or NADPH, 0.5 M Na-phosphate buffer (pH 6.1) and for butanediol dehydrogenase activity the gel was incubated for 15 minutes with 72 mM butanediol, 1 mM NAD+ or NADP+, 0.5 M Na-phosphate buffer. The gel was next incubated for 30 minutes under dry conditions before the addition of a solution consisting of 0.02 mM Meldola's blue (8-Dimethylamino-2,3-benzophenoxazine), 0.08 mM MTT (3-[4,5-Dimethylthiazol-2yl] 2,5-diphenyltetrazolium bromide; Thiazolyl blue) in 100 mM phosphate buffer (pH 8.2) (Provecho et al, 1984; Gibson et al, 1991). Visible protein bands appeared within 20 minutes.

(vii) Cell-free extracts

25 DB1334, MW008 and MM084 were cultivated in M17 (0.5% glucose) until mid exponential phase. The cells were harvested by centrifugation at 6000 rpm for 15 minutes and washed in cold 50 mM Na-phosphate buffer (pH 6). The pellet was resuspended in cold 50 mM Na-phosphate buffer (pH 6) and sonicated for 3 x 2 minutes. The sonicated cell mixture was centrifuged at 6000 rpm for 15 minutes and the supernatant was stored at -20°C until analysed for protein concentration and enzyme activities.

(vii) Enzyme activity measurements

Diacetyl reductase activity was measured spectrophotometrically by monitoring the oxidation of NADH or NADPH at 340 nm in a reaction mixture with the following composition: 50 mM Na-phosphate buffer (pH 6.1), 36 mM diacetyl and 0.5 mM NADH or NADPH. Butanediol dehydrogenase activity was measured spectrophotometrically by monitoring the reduction of NAD+ or NADP+ at 340 nm in a reaction mixture with the following composition: 50 mM Na-phosphate buffer (pH 6.1), 72 mM butanediol and 0.5 mM NAD+ or NADP+. Acetoin reductase activity was measured spectrophotometrically by monitoring the oxidation of NADH or NADPH at 340 nm in a reaction mixture with the following composition: 50 mM Na-phosphate buffer (pH 6.1), 36 mM acetoin and 0.5 mM NADH or NADPH. Lactate dehydrogenase activity was measured by monitoring the oxidation of NADH at 340 nm in a reaction mixture with the following composition: 50 mM Tris-acetate buffer (pH 6), 0.5 mM fructose-1,6-diphosphate, 25 mM pyruvate and 0.5 mM NADH. The specific activities of the enzymes were expressed as micromoles of converted substrate per milligram of protein per minute (equivalent to units per milligram protein).

(viii) Protein determination

20

Protein concentration was measured by using the BCA Protein Assay Reagent (Pierce) with bovine serum albumin as the standard.

2.3. Results

25

(i) Screening of EMS mutagenized MW008

Based on the previous results that diacetyl reductase is also able to react with butanediol and NADP⁺ (see Example 1), mutagenized MW008 was screened by incubating the cells in a solution consisting of butanediol and NADP⁺. Possible mutants were colourless whereas cells with an intact diacetyl reductase were stained purple. Approximately 3500 clones were screened with the zymogram method. Two possible mutants were further restreaked three times and repeatedly restained with

Meldola's blue and MTT. One of the two possible clones was found to be an NADPH-dependent diacetyl reductase mutant. This clone was designated MM084.

A sample of the mutant Leu. pseudomesenteroides MM084 strain was deposited in accordance with the Budapest Treaty with the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), Marschenroder Weg, 1b, D-38124 Braunschweig on 28 October 1998 under the Accession No. DSM12465.

(ii) Enzyme activity measurements

10

Cell free extracts of DB1334, MW008 and MM084 were used for measuring diacetyl reductase, acetoin reductase and butanediol dehydrogenase activities. As a positive control for the activity of the strains, lactate dehydrogenase activity was also measured. The enzyme activities of DB1334, MW008 and MM084 are summarised in Table 2.1. Values for lactate dehydrogenase activities of the mutants were comparable to the wild-type strain (data not shown).

Table 2.1. Diacetyl reductase (DR), acetoin reductase (AR), and butanediol dehydrogenase (BUTDH) activities from cell free extracts of DB1334, MW008, and MM084.

strain			specific ac	tivity (U/mg)		
	DR		AR		BUTDH	
	NADH	NADPH	NADH	NADPH	NADT	NADP*
DB1334	2.81	1.47	0.81	0.77	0.34	0.16
MW008	0.017	1.27	n.d	0.84	n.d	0.14
MM084	n.d	n.d	n.d	n.d	n.d	n.d

n.d = not detectable, activities below the detection limit < 0.005 U/mg.

25 (iii) Zymogram stained native-PAGE gels

Native-PAGE gels run with cell extracts from DB1334 and MM084 and incubated with diacetyl + NADPH, and butanediol + NADP+ showed that MM084 possessed no activities with these substrates and cofactors (Fig. 2).

2.4. Conclusions

It has been shown that wild-type *Leu. pseudomesenteroides* is capable of reducing diacetyl into acetoin and butanediol due to diacetyl reductase activities using either NADH or NADPH as cofactors.

An NADH-dependent diacetyl reductase mutant was capable of reducing diacetyl at the same rate as that of the wild-type strain during milk fermentation. When using NADPH as cofactor, the mutant had enzyme activities comparable to the wild-type strain. Mutagenesis and screening of MW008 with the zymogram technique resulted in the isolation of an NAD(P)H-dependent diacetyl reductase mutant. Such a mutant would be incapable of reducing diacetyl into acetoin and butanediol by means of diacetyl reductase.

15

EXAMPLE 3

Effect of diacetyl reductase deficient Leuconostoc pseudomesenteroides strain MM084 on diacetyl stability in fermented dairy products under storage

20

3.1. Introduction

As described in Example 2, the diacetyl reductase mutant MM084 is isolated as a double mutant of *Leuconostoc pseudomesenteroides* strain DB1334 and lacks both NADH and NADPH dependent DR.

When cultivated in milk as a pure culture, MM084 does not reduce diacetyl and acetoin. Due to this characteristic, mutant MM084 is assumed to be a suitable strain for use as a component in mesophilic cultures which results in an improved diacetyl stability in the fermented products. In this Example, the effect of the mutant MM084 on flavour formation and stability in fermented milk was investigated with main focus on the concentration of diacetyl.

3.2. Materials and methods

(i) Bacterial strain

5 The strains used in this example originate from the Chr. Hansen Culture Collection:

Lactococcus lactis subsp. lactis DB1387 (O strain);

Lactococcus lactis subsp. lactis biovar. diacetylactis strain DB1341 (D strain);
Lactococcus lactis subsp. lactis biovar. diacetylactis -acetolactate decarboxylase

O deficient mutant MC010 (Curic et al. 1999) (D strain);

Leuconostoc pseudomesenteroides DB1334 (L strain);

Leuconostoc pseudomesenteroides DR mutant MM084 (L strain).

Mixed cultures were composed of three different strains. Strains were produced as frozen pellets and stored at -50°C. The prepared inoculum contained 1.5 x 10⁸ CFU/ml.

The following mixed culture were used in this example:

A) DB1387 + DB1341 + DB1334

20 B) DB1387 + DB1341 + MM084

C) DB1387 + MC010 + DB1334

D) DB1387 + MC010 + MM084

Mixed culture A and C were used as a control.

25 (ii) Cultivation medium

Reconstituted skimmed milk (9.5%); 200 ml in 250 ml bottles. Cream: Commercially available dairy cream (13%) was adjusted to 11% fat by addition of skimmed milk, distributed in 500 ml bottles, re-pasteurised at 85°C for 30 min and cooled to 22°C

30 prior to inoculation.

(iii) Cultivation conditions

The milk or cream was inoculated with a total of 1% of inoculum and incubated at 22° C until pH reached 4.60 \pm 0.05. Following incubation, the bottles were kept at 4° C.

(iv) Determination of fermentation product formation

Samples for analysing the product formation were taken immediately after inoculation, during fermentation and during storage. Concentrations of the volatile compounds ethanol, acetaldehyde, -acetolactate, acetoin and diacetyl were determined by HSGC (Richelieu et al., 1997).

3.3 Results and discussion

No significant differences in the acidification rate were observed between milk fermented with cultures containing DR MM084 (B and D) and the control mixed cultures (A and C) (results not shown). At the end of the fermentation, all four mixed cultures produced similar amounts of ethanol and acetaldehyde. In all mixed cultures except culture D, acetaldehyde was reduced until the end of the fermentation (results not shown). Excess of acetaldehyde may cause yoghurt-like flavour of buttermilk, which is considered as an off-flavour. However, the concentration of acetaldehyde with mixed culture D is reduced during the first 2-3 days of storage.

25 It is shown that reduction of the diacetyl reductase activity of the *Leuconostoc* strain MM084 has a significant effect on the stability of diacetyl during storage (Tables 3.1 and 3.2, Fig. 3 and 4). The diacetyl content in the medium at the end of the fermentation is significantly higher in mixed cultures containing MM084 (B and D) as compared to the control mixed cultures (A and C).

Table 3.1. Diacetyl concentrations in milk, fermented by the mixed cultures A and B, during fermentation and storage.

Ti	me (h)	Diacetyl (mg/L)		
•		Mixed culture A	Mixed culture B	
Fermentation	0	0.0	0.0	
	13	0.3	0.3	
<u> </u>	15	1.2	0.7	
•	17	2.0	1.1	
	19	1.8	1.4	
	21	1.0	1.6	
	22	0.5	1.4	
Storage	46 (+1day)	0.3	0.9	
	94 (+3days)	0.2	0.8	
	142 (+5days)	0.0	0.7	
	190 (+7days)	0.0	0.6	
,	358 (+14days)	0.0	0.6	
	502 (+ 20days)	0.0	0.7	

5 Table 3.2 Diacetyl concentrations in sour cream fermented by the mixed cultures C and D during fermentation and storage.

7	ime (h)	Diacetyl (mg/L)		
		Mixed culture C	Mixed culture D	
Fermentation	0	0.0	0.0	
	12	3.7	2.3	
	13	5.5	4.6	
	14	7.1	9.7	
	15	9.4	12.8	
. `	16	8.5	12.4	
	17	8.0	9.6	
Storage	41 (+1day)	1.9	5.4	
	113 (+4days)	0.5	4.6	
'	161 (+6days)	0.6	4.2	
	305 (+12days)	0.3	2.0	
,	689 (+28days)	0.1	0.8	
	857 (+35days)	0.1	0.9	
	1025 (+42 days)	0.1	1.0	

The sour cream fermented with the cultures C and D was sensorically evaluated after 1, 7, 14, 21, and 28 days, respectively. The sour cream had a mild, clean and fresh flavour. The fresh flavour was maintained during a prolonged storage.

5 3.4. Conclusion

The strain MM084 is suitable for use as a component of a mixed aroma-forming culture. The mixed cultures composed with MM084 had a significantly improved diacetyl stability during storage and a significant higher content of diacetyl at the end of fermentation and after storage. Such a mixed culture is beneficial in the production of sour cream and cream cheeses.

EXAMPLE 4

15

Isolation and characterisation of a Lactococcus lactis subsp. lactis mutant with enhanced diacetyl reductase activity

4.1. Introduction

20

The *L. lactis* subsp. *lactis* mutant strain DN223 is both a lactate dehydrogenase (LDH) and pyruvate formate lyase (PFL)defective. DN223 is strictly aerobic and the lack of capability to grow anaerobically (even in the presence of acetate) is most likely due to a constraint on the intracellular redox balance, as the net consumption of NAD⁺ in the glycolysis can no longer be regenerated due to the two enzymatic defects. Exogenous acetoin was expected to assist in the regeneration of NAD⁺ under anaerobic conditions by conversion into 2,3-butanediol by the enzyme diacetyl reductase (DR).

4.2. Isolation of a mutant with enhanced DR activity

30

A test tube containing 10 ml of DN medium (Dickely et al., 1995) supplemented with acetate was inoculated with a single colony of DN223 picked from an agar plate and incubated aerobically overnight at 30°C. 100 μ l of the overnight culture was spread onto two agar plates containing DN medium supplemented with 2.0 g/L sodium

acetate trihydrate and 0.5 g/L acetoin and incubated anaerobically for two days at 30°C. A number of colonies were subsequently streaked onto agar plates containing DN medium supplemented with acetate and with and without 0.5 g/L acetoin and incubated anaerobically for two days at 30°C. One mutant designated CMH-153 was isolated which only displayed anaerobic growth if the medium was supplemented with 0.5 g/L acetoin.

A sample of the *L. lactis* subsp. *lactis* CMH-153 strain was deposited in accordance with the Budapest Treaty with the Deutsche Sammlung vor Mikroorganismen und 2 Zellkulturen (DSMZ), Marschenroder Weg, 1b, D-38124 Braunschweig on 7 April 1998 under the Accession No. DSM 12096.

4.3. Characterisation of L. lactis CMH-153

- 15 200 ml of DN medium supplemented with acetate was inoculated with a single colony of CMH-153 picked from an agar plate and incubated aerobically overnight at 30°C. Subsequently, a cell-free extract was made and the protein content of the extract was measured.
- 20 The diacetyl activities of strain CMH-153 were measured with diacetyl as substrate and NADH as cofactor and are expressed as the units of [μmoles NADH consumed per min. per mg of protein] according to the assay described in Example 1. The diacetyl activities of strain CMH-153 were compared with other *L. lactis* subsp. *lactis* strains (Table 4.1).
- Additionally, the diacetyl activities of strain CHM-153 were measured using either diacetyl, acetoin or 2,3-butanediol as substrate and NADH, NAD+, NADPH or NADP+ as cofactor and are expressed as units of [μmoles NADH or NADPH produced or consumed per min. per mg of protein] according to the assay described in Example 1.

 30 The diacetyl activities of strain CMH-153 were compared with other *L. lactis* subsp.
- 30 The diacetyl activities of strain CMH-153 were compared with other *L. lactis* subsp. *lactis* strains (Table 4.2).

Table 4.1. Diacetyl reductase activity of CMH-153 compared with other *L. lactis* subsp. *lactis* strains.

Strain	Phenotype	Specific activity
CHCC373	Wild-type	n.d.
DN221	Pfl ⁻	n.d.
DN223	Pfl'/Ldh	0.01-0.02
DN224	Ldh	0.01
CMH-153	Pfl'/Ldh'/Dr++	0.92

5 n.d = not detectable, activities below the detection limit < 0.005 U/mg.

Table 4.2 Diacetyl reductase activity of CMH-153 compared with other *L. lactis* subsp. *lactis* strains

	Strains			
Enzymatic reaction	Co-factor	CHCC373	DN223	CMH-153
diacetyl > acetoin	NADH	n.d.	n.d.	1.15
	NADPH	n.d.	n.d.	0.04
acetoin> diacetyl	NAD+	n.d.	n.d.	n.d.
	NADP+	n.d.	n.d.	n.d.
acetoin> 2,3-butanediol	NADH	0.02	0,07	0.41
	NADPH	n.d.	n.d.	0.02
2,3-butanediol > acetoin	NAD+	n.d.	n.d.	0.12
	NADP+	n.d.	n.d.	n.d.

10

n.d = not detectable, activities below the detection limit < 0.005 U/mg.

Finally, the specific LDH activity of strain CMH-153 was measured using the method as also described in Example 1 and compared with other *L. lactis* subsp. *lactis* strains
15 (Table 4.3). Activities are expressed as units of [μmoles NADH consumed per min. per mg of protein].

Table 4.3. Lactate dehydrogenase activity of CMH-153 compared with other *L. lactis* subsp. *lactis* strains

Strain	Phenotype	Specific activity
CHCC373	Wild-type	15.3
DN221	Pfl	15.3
DN223	Pfl'/Ldh'	n.d.
DN224	Ldh	n.d.
CMH-153	Pfl'/Ldh'/Dr++	n.d.

5 $\,$ n.d = not detectable, activities below the detection limit < 0.005 U/mg.

The specific diacetyl reductase activities of CMH-153 are significantly increased compared to other *L. lactis* strains with various phenotypes (Table 4.1 and 4.2) whereas CMH-153 has no detectable LDH activity (Table 4.3). Thus, the mutant strain 10 *L. lactis* subsp. *lactis* CMH-153 has the phenotype Ldh/Pfl/Dr⁺⁺, as it is only capable of anaerobic growth if supplied with acetoin and acetate.

REFERENCES

Arora, B.C., Dutta, S.M., Sabharwal, V.B. and Ranganathan, B. (1978). Mutants of Streptococcus lactis subsp. diacetylactis lacking diacetyl reductase activity. Acta Microbiol Pol 27:353-358.

Boumerdassi, H., Monnet, C., Desmazeaud and M., Corrieu, G. (1997). Isolation and properties of *Lactococcus lactis* subsp. *lactis* biovar *diacetylactis* CNRZ 483 mutants producing diacetyl and acetoin from glucose. Appl. Environ. Microbiol. **63**: 2293-10 2299.

Crow, V.L. (1990). Properties of 2,3-butanediol dehydrogenases from *Lactococcus lactis* subsp. *lactis* in relation to citrate fermentation. Appl. Environ. Microbiol. **56**:1656-1665.

15 -

Curic, M., Lauridsen, B. S., Renault, P. and Nilsson, D. (1999). A general method for selection of -acetolactate decarboxylase deficient *Lactococcus lactis* mutants to improve diacetyl formation. Appl. Environ. Microbiol. **63**:1202-1206.

- 20 Dickely, F., Nilsson, D., Hansen, E.B. and Johansen, E. (1995). Isolation of Lactococcus lactis nonsense suppressors and construction of a food-grade cloning vector. Mol. Microbiol. **15**:839-847.
- Gibson, T.D., Parker, S.M. and Woodward, J.R. (1991). Purification and characterization of diacetyl reductase from chicken liver and *Streptococcus lactis* and enzymatic determination of diacetyl and ketones. Enz. Microb. Technol. **13**:171-178.

Giovannini, P.P., Medici, A., Bergamini, C.M. and Rippa, M. (1996). Properties of diacetyl (acetoin) reductase from *Bacillus stearothermophilus*. Bioorg. Med. Chem. 30 4:1197-1201.

Kulia, R.K. and Ranganathan, B. (1978). Ultraviolet light-induced mutants of *Streptococcus lactis* subsp. *diacetylactis* with enhanced acid- or flavor-producing abilities. J. Dairy Sci. **61**:379-383.

Provecho, F., Burgos, J. and Sarmiento, R.M. (1984). Further purification and characterization of diacetyl reducing enzymes from beef liver. Int. J. Biochem. **16**:423-427.

5

Richelieu, M., Houlberg, U. and Nielsen, J.C. (1997). Determination of α -acetolactic acid and volatile compounds by headspace gas chromatography. J. Dairy Sci. 80:1918-1925.

10 Terzaghi, B.E. and Sandine, W.E. (1975). Improved medium for *Lactic streptococci* and their bacteriophages. Appl. Microbiol. **29**:807-813.

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism reference on page 30, line 8	rred to in the description
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
DSMZ-Deutsche Sammlung von Mikroon	ganismen und Zellkulturen GmbH
Address of depositary institution (including postal code and country)	1
Mascheroder Weg 1B D-38124 Braunschweig Germany	
Date of deposit	Accession Number
7 April 1998	DSM 12096
C. ADDITIONAL INDICATIONS (leave blank if not applicable	(e) This information is continued on an additional sheet
nated states, the applicants required microorganisms only be made a	vailable to an expert nominated
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn.	vailable to an expert nominated
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn.	vailable to an expert nominated on which the patent is granted or has been refused or withdrawn or
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn.	vailable to an expert nominated on which the patent is granted or n has been refused or withdrawn or
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn.	vailable to an expert nominated on which the patent is granted or n has been refused or withdrawn or
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn.	vailable to an expert nominated on which the patent is granted or n has been refused or withdrawn or
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (learning of the second of t	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (learning of the second of t	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear The indications listed below will be submitted to the International Control of the Inter	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear The indications listed below will be submitted to the International Control of the Inter	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear The indications listed below will be submitted to the International Control of the Inter	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear The indications listed below will be submitted to the International Control of the Inter	evailable to an expert nominated on which the patent is granted or in has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable)
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear Number of Deposit*)	wailable to an expert nominated on which the patent is granted or has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) If Bureau later (specify the general nature of the indications e.g., "Accession For International Bureau use only
ted microorganisms only be made a by the requester until the date of the date on which the application is deemed to be withdrawn. D. DESIGNATED STATES FOR WHICH INDICATION E. SEPARATE FURNISHING OF INDICATIONS (lear Number of Deposit*) For receiving Office use only	wailable to an expert nominated on which the patent is granted or has been refused or withdrawn or one of the indications are not for all designated States) ONS ARE MADE (if the indications are not for all designated States) we blank if not applicable) If Bureau later (specify the general nature of the indications e.g., "Accession For International Bureau use only

Form PCT/RC/134 (Lily 1992)

INDICATIONS RELATING TO DEPOSITED MICROORGANISMS (PCT Rule 12bis)

5

Additional sheet

In addition to the microorganism indicated on page 35 of the description, the following microorganisms have been deposited with

10 DSM-Deutsche Sammlung von Mikroorganismen und Cellkulturen GmbH Mascheroder Weg 1b, D-38124 Braunschweig, Germany

on the dates and under the accession numbers as stated below:

15	Accession number	Date of deposit	Description Page No.	Description Line No.
20	DSM 12099 DSM 12465	7 April 1998 28 Oct.1998	19 24	4 4

25 For all of the above-identified deposited microorganisms, the following additional indications apply:

As regards the respective Patent Offices of the respective designated states, the applicants request that a sample of the deposited microorganisms stated above only be made available to an expert nominated by the requester until the date on which the patent is granted or the date on which the application has been refused or withdrawn or is deemed to be withdrawn.

CLAIMS

15

30

- A genetically modified lactic acid bacterium, including the Leuconostoc pseudome-senteroides strains DSM 12099 and DSM 12465 and lactic acid bacteria essentially
 having the diacetyl reductase characteristics of these strains, that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, said modified bacterium,
- 10 (i) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADH and not containing NADH, or
 - (ii) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADPH and not containing NADH, or
 - (iii) is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing both NADH and NADPH, or
- (iv) is substantially incapable of butanediol dehydrogenase activity in a medium 20 containing NAD+ and not containing NADP+, or
 - (v) is substantially incapable of butanediol dehydrogenase activity in a medium containing NADP+ and not containing NAD+, or
- 25 (vi) is substantially incapable of butanediol dehydrogenase activity in a medium containing both NAD⁺ and NADP⁺,
 - where the bacterium prior to being modified is capable of having at least one of said enzymatic activities under said cofactor conditions.
 - 2. A bacterium according to claim 1 that is selected from the group consisting of Lactococcus spp., Streptococcus spp., Lactobacillus spp., Leuconostoc spp., Pediococcus spp., Oenococcus spp. and Bifidobacterium spp.

- 3. A bacterium according to claim 2 that is Leuconostoc pseudomesenteroides.
- 4. A genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have a reduction of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, including the *Leuconostoc pseudomesenteroides* strains DSM 12099 and DSM 12465 and lactic acid bacteria essentially having the diacetyl reductase characteristics of these strains, subject to the limitation, that the lactic acid bacterium is not *Lactococcus lactis*.

10

5. A bacterium according to claim 4 that under cofactor conditions, where the bacterium prior to being modified is capable of having at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity, is substantially incapable of at least one of said enzymatic activities.

15

- 6. A bacterium according to claim 5 that is incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADH and not containing NADPH.
- 7. A bacterium according to claim 5 that is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing NADPH and not containing NADH.
- 8. A bacterium according to claim 5 that is substantially incapable of at least one of diacetyl reductase activity and acetoin reductase activity in a medium containing both NADH and NADPH.
 - 9. A bacterium according to claim 5 that is substantially incapable of butanediol dehydrogenase activity in a medium containing NAD⁺ and not containing NADP⁺.

30

10. A bacterium according to claim 5 that is substantially incapable of butanediol dehydrogenase activity in a medium containing NADP⁺ and not containing NAD⁺.

- 11. A bacterium according to claim 5 that is substantially incapable of butanediol dehydrogenase activity in a medium containing both NAD⁺ and NADP⁺.
- 12. A bacterium according to claim 4 that is selected from the group consisting of
 5 Lactococcus spp., Streptococcus spp., Lactobacillus spp., Leuconostoc spp.,
 Pediococcus spp., Oenococcus spp. and Bifidobacterium spp.
 - 13. A bacterium according to claim 12 that is Leuconostoc pseudomesenteroides.
- 10 14. A bacterium according to claim 1 or 4 that is derived by subjecting a parent lactic acid bacterial strain that under appropriate cofactor conditions is capable of having diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase activity to a mutagenization treatment and selecting a strain that is substantially incapable of at least one of said enzymatic activities under identical cofactor
 15 conditions.
 - 15. A bacterium according to claim 14 that is derived by contacting the parent strain with a chemical mutagen or UV light.
- 20 16. A bacterium according to claim 14 that is derived by recombinant DNA technology.
- 17. A genetically modified lactic acid bacterium that has no detectable diacetyl reductase activity, acetoin reductase activity and/or butanediol dehydrogenase
 25 activity, subject to the limitation, that the lactic acid bacterium is not *Lactococcus lactis*.
 - 18. A bacterium according to claim 17 that is selected from the group consisting of Lactococcus spp., Streptococcus spp., Lactobacillus spp., Leuconostoc spp.,
- 30 Pediococcus spp. and Bifidobacterium spp.
 - 19. A bacterium according to claim 18 that is Leuconostoc pseudomesenteroides.

- 20. A genetically modified lactic acid bacterium that, relative to the lactic acid bacterium from which it is derived, is modified to have an enhancement of at least one of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity which is at least 10 times, including the *Lactococcus lactis* subsp. *lactis* strain DSM 12096 and lactic acid bacteria essentially having the diacetyl reductase characteristics of that strain.
 - 21. A bacterium according to claim 20 that is selected from the group consisting of Lactococcus spp., Streptococcus spp., Lactobacillus spp., Leuconostoc spp.,
- 10 Pediococcus spp., Oenococcus spp. and Bifidobacterium spp.
 - 22. A bacterium according to claim 21 that is Lactococcus lactis.
- 23. A starter culture composition comprising a bacterium according to anyone of claims 1-19.
 - 24. A starter culture composition comprising a bacterium according to anyone of claims 20-22.
- 20 25. A composition according to claim 23 or 24 that is a freeze-dried composition.
 - 26. A composition according to claim 25 containing an amount of viable lactic acid bacteria which is in the range of 10⁴ to 10¹² cfu per g.
- 25 27. A method of preparing a fermented food product, comprising adding an effective amount of a bacterium according to any of claims 1-19 or the composition of claim 23 to a food product starting material wherein the bacterium or the composition is incapable of having at least one enzymatic activity selected from the group consisting of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity and keeping the starting material under conditions where the bacterium or the starter culture composition is capable of fermenting said starting material to obtain the fermented food.

- 28. A method according to claim 27 wherein the starting material is selected from the group consisting of milk, a vegetable material, a meat product, a fruit juice, a must, a wine, a dough and a batter.
- 5 29. A method according to claim 28 wherein the resulting fermented food product is a dairy product including a product selected from the group consisting of cheese and buttermilk.
- 30. A fermented food product obtainable by the method of any of claims 27-29 which product initially has a content of diacetyl which is at least 10% higher than that of a product fermented under identical conditions with a parent strain for the genetically modified bacterium.
- 31. A food product according to claim 30 that is selected from the group consisting of a milk-based product, a vegetable product, a meat product, a fruit juice, a wine and a bakery product.
 - 32. A food product according to claim 31 that is selected from the group consisting of cheese and buttermilk.
- 20
- 33. A food product according to claim 30 in which at least 10% of its initial diacetyl content is retained after storage for 20 days or more at about 4°C.
- 34. A method of producing a food product, comprising adding an effective amount of a bacterium according to anyone of claims 20-22 or the composition of claim 24 to a food product starting material that contains at least one of diacetyl, acetoin and butanediol, and keeping the starting material under conditions where the genetically modified lactic acid bacterium has at least one enzymatic activity selected from the group consisting of diacetyl reductase activity, acetoin reductase activity and butanediol dehydrogenase activity to obtain a product having a reduced content of diacetyl.
 - 35. A method according to claim 34 wherein the food product starting material is a yeast fermented beverage including beer and wine.

36. A method according to claim 34 wherein the resulting product has no detectable content of diacetyl.





Fig. 1

Diacetyl + NADPH

2/4






Fig. 2




Fig. 3




Fig. 4

INTERNATIONAL SEARCH REPORT

Inte onal Application No PCT/DK 99/00218

CLASSIFICATION OF SUBJECT MATTER PC 6 C12N15/01 C12N C12N15/74 C12N1/20 C12N9/04 IPC 6 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category " 1,2,4,5, KUILA R K AND RANGANATHAN B: "Ultraviolet 12,14, light-induced mutants of Streptococcus 15,17, lactis subspecies diacetylacis with 18,20-34enhanced acid- or flavor-producing abilities" JOURNAL OF DAIRY SCIENCE, vol. 61, no. 4, 1978, pages 379-383, XP002086554 the whole document 1,2,4,5. ARORA B C ET AL: "Mutants of Α 12,14. Streptococcus lactis subsp. diacetylactis 15,17. lacking diacetyl reductase activity" 18,23. ACTA MICROBIOLOGICA POLONICA, 25-29. vol. 27, no. 4, 1978, pages 353-358. 34-36 XP002086555 cited in the application the whole document Patent family members are listed in annex. Further documents are listed in the continuation of box C. "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the Special categories of cited documents "A" document defining the general state of the lart which is not considered to be of particular relevance invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone earlier document but published on or after the international document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 28/07/1999 21 July 1999 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Oderwald, H

INTERNATIONAL SEARCH REPORT

Inte onal Application No PCT/DK 99/00218

C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	 Relevant to claim No.	
Category '	Citation of document, with indication, where appropriate, of the relevant passages	neievant to cidim No.	_
	CROW V L: "Properties of 2,3-butanediol dehydrogenases from Lactococcus lactis subsp. lactis in relation to citrate fermentation" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 56, no. 6, June 1990 (1990-06), pages 1656-1665, XP002086556 cited in the application abstract; figures 4-6; tables 1,2	1,2,4,5, 12,20, 21,23, 24,34	
•	page 1656 page 1660 - page 1662 	1 2 4 5	
A	BOUMERDASSI H ET AL: "Isolation and properties of Lactococcus lactis subsp. lactis biovar diacetylactis CNRZ 483 mutants producing diacetyl and acetoin from glucose" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 63, no. 6, June 1997 (1997-06), pages 2293-2299, XP002086557 the whole document	1,2,4,5,	
A	EP 0 199 105 A (DOHLER GMBH) 29 October 1986 (1986-10-29) the whole document JAKUBOWSKA J ET AL: "Evaluation of lactic acid streptococci for the preparation of frozen concentrated starter cultures"		
	ACTA MICROBIOLOGICA POLONICA, vol. 29, no. 2. 1980, pages 135-144, XP002086558 the whole document		

INTERNATIONAL SEARCH REPORT

information on patent family members

Inte onal Application No PCT/DK 99/00218

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0199105	A	29-10-1986	DE DK JP	3512814 A 160386 A 61293372 A	30-10-1986 11-10-1986 24-12-1986